



## Drug–Drug Interactions

Guest Editors:

**Prof. Dr. Dong Hyun Kim**

Department of Pharmacology  
and Pharmacogenomics  
Research Center, Inje University  
College of Medicine, Inje  
University, Busan 47392,  
Republic of Korea

**Prof. Dr. Sangkyu Lee**

College of Pharmacy and  
Research Institute of  
Pharmaceutical Sciences,  
Kyungpook National University,  
Daegu, Republic of Korea

Deadline for manuscript  
submissions:

**closed (31 July 2020)**

### Message from the Guest Editors

Dear Colleagues,

Drug–drug interactions (DDIs) cause one drug to affect other drugs, leading to a reduced drug efficacy or an increased toxicity of the affected drugs. Traditionally, DDIs have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs based on CYPs is very important, but recently, other important mechanisms have also been studied as contributing to the drug interactions, such as drug transporter- or UDP-glucuronyltransferase-mediated DDI. In addition, the novel mechanism to regulate DDI can also be suggested. In the case of the substance to be interacted, not only the DDI, but also the herb- or food–drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or a new mechanism study will be very helpful for preventing the side effects of the patient taking them. This Special Issue has the aim of highlighting the current progress in the clinical or non-clinical interactions of commercial drugs and the elucidation of the mechanism of drug interactions.

Prof. Dong Hyun Kim

Prof. Sangkyu Lee

Guest Editors





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceutics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma